Opus Genetics doses first patient in phase 3 LYNX-3 trial evaluating phentolamine ophthalmic solution 0.75%

Published on September 9, 2025
The trial will evaluate the solution in treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision.
Continue reading on website
Other news

Harrow Announces Offering of $250 Million Senior Unsecured Notes Due in 2030

September 9, 2025
NASHVILLE, Tenn.—Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, announced that it has commenced with a private offering of $250 million aggregate principal amount in senior unsecured notes due in 2030, subject to market and other conditions. The 2030 Notes will be guaranteed on a senior unsecured basis by the company’s existing and future whol

Real-World Study Shows Positive Pegcetacoplan Results for Geographic Atrophy

September 9, 2025
The study, published in American Journal of Ophthalmology, showed pegcetacoplan to be more effective than in the clinical trials. However, study participants experienced significant loss of BCVA and eyes with prior anti-VEGF treatment were more likely to develop exudation. Despite this, the researchers concluded pegcetacoplan to be “safe and effective” in the real-world setting. Photo: Paul Karpec